Trump’s New Drug Advertising Proposals Fall Short on Public Health and the Constitution

Key Takeaways

• Compounding disclosure would label unreviewed drugs as misbranded.
• Proposal gives FDA authority to criminalize misleading DTC ads.
• Existing law already curbs false drug advertising; new rule adds subjectivity.
• Restricting truthful ads could reduce patient awareness of treatable conditions.
• Congress can adopt disclosure while rejecting overbroad ad restrictions.

Pulse Analysis

The FDA’s FY 2027 budget request reflects a growing focus on transparency in the booming compounding market. After the 2025 GLP‑1 shortage, pharmacies like Hims & Hers flooded the market with compounded semaglutide, often without clear warnings that the products had never undergone FDA review. A mandatory disclosure—similar to odometer certifications for used cars—would give patients a factual baseline, reducing the risk of adverse events from unvetted formulations and aligning with the agency’s consumer‑protection mandate.

At the same time, the proposal to broaden FDA authority over direct‑to‑consumer (DTC) advertising raises constitutional concerns. Current regulations already require balanced risk‑benefit statements and allow the agency to issue warning letters for deceptive claims. Granting the power to label ads criminally misbranded based on vague “misleading impressions” would introduce subjective judgments, chilling truthful speech and potentially stifling public awareness of new treatments for chronic diseases such as diabetes, depression, and HIV. Legal precedent, notably *Thompson v. Western States Medical Center*, demands the least intrusive means to achieve a substantial public‑health interest, a standard the new language appears to bypass.

Policymakers face a clear choice: embrace the low‑burden, high‑impact disclosure rule that safeguards patients buying compounded drugs, while preserving the existing, narrowly tailored framework for DTC advertising. By rejecting the overbroad ad restrictions, Congress can uphold First Amendment protections, maintain a critical conduit for patient education, and avoid unintended public‑health setbacks that arise when patients remain uninformed about FDA‑approved therapies. This balanced approach supports both consumer safety and a vibrant, transparent pharmaceutical market.